Heloni Dave

Feb 1, 2024 | ccjm.org | Heloni Dave |Alok Khorana

KEY POINTS Patients with cancer are at a much higher risk of developing VTE than the general population. Low-molecular-weight heparin or direct oral anticoagulants are preferred over vitamin K antagonists. Direct oral anticoagulants are generally preferred, but caution is needed in patients at risk of bleeding.